diethazine: phenothiazine derivative anti-Parkinson agent with anticholinergic and antihistaminic actions; is effective against Parkinson tremor; minor descriptor (75-86); on-line & INDEX MEDICUS search PHENOTHIAZINES (75-86); RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65535 |
| CHEMBL ID | 1620412 |
| CHEBI ID | 135265 |
| SCHEMBL ID | 142924 |
| MeSH ID | M0263232 |
| Synonym |
|---|
| 10h-phenothiazine-10-ethanamine, n,n-diethyl- |
| diethazine |
| diethazine [inn:ban] |
| dietazina [inn-spanish] |
| eazamine |
| einecs 200-491-3 |
| 10-(2-diethylaminoethyl)phenothiazine |
| lodibon |
| dolisina |
| diaethazinum |
| fourneau 2987 |
| latibon |
| n-(diethylaminoethyl)thiodiphenylamine |
| casantin [german] |
| diethazinum [inn-latin] |
| n-(2'-diethylaminoethyl)dibenzoparathiazine |
| phenothiazine, 10-(2-(diethylamino)ethyl)- |
| parkazin |
| 60-91-3 |
| n,n-diethyl-2-phenothiazin-10-yl-ethanamine |
| diathazine |
| CHEBI:135265 |
| n,n-diethyl-2-phenothiazin-10-ylethanamine |
| D07823 |
| diethazine (inn) |
| AKOS005066642 |
| CHEMBL1620412 , |
| NCGC00245630-01 |
| bdbm50339139 |
| casantin |
| dietazina |
| diethazinum |
| unii-28b5cg0ru3 |
| 28b5cg0ru3 , |
| SCHEMBL142924 |
| AB00109874-01 |
| diethazine [who-dd] |
| diethazine [inn] |
| diethazine [mi] |
| dinezin (salt/mix) |
| diethazin |
| ethylemin |
| thiantan (salt/mix) |
| n-[2'-(diethylamino)ethyl]dibenzo-p-thiazine |
| diparcol (salt/mix) |
| n,n-diethyl-2-(10h-phenothiazin-10-yl)ethanamine # |
| eazaminum |
| 10(beta-diethylaminoethyl)-phenothiazine |
| phenothiazine, 10-[2-(diethylamino)ethyl]- |
| deparkin (salt/mix) |
| latibon (salt/mix) |
| 2987 r.p. |
| antipar (salt/mix) |
| LURMIKVZJSMXQE-UHFFFAOYSA-N |
| dinezine (salt/mix) |
| DTXSID40208700 |
| 10-(2-diethylaminoethyl)-phenothiazine diethazine |
| CCG-358878 |
| Q27254297 |
| Z2681892262 |
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 (µMol) | 10.3000 | 1.3000 | 3.3727 | 9.6000 | AID581672 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Snq2p | Saccharomyces cerevisiae EC1118 | INH | 239.0000 | 3.2000 | 6.2600 | 8.8000 | AID581808 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | INH | 331.0000 | 4.2000 | 6.1833 | 8.3000 | AID581806 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID581806 | Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID581672 | Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID581808 | Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID581807 | Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 17 (89.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||